169 related articles for article (PubMed ID: 34581433)
21. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes.
Magnusson E; Cao Q; Linden MA; Frolich J; Anand V; Burns LJ; Bachanova V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):114-21. PubMed ID: 24388482
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.
Adrianzen Herrera D; Kornblum N; Derman O; Bachier-Rodriguez L; Sica RA; Shastri A; Janakiram M; Verma A; Braunschweig I; Mantzaris I
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):516-521. PubMed ID: 31227357
[TBL] [Abstract][Full Text] [Related]
24. Mantle Cell Lymphoma: Which Patients Should We Transplant?
Gerson JN; Barta SK
Curr Hematol Malig Rep; 2019 Aug; 14(4):239-246. PubMed ID: 31218478
[TBL] [Abstract][Full Text] [Related]
25. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma.
Dietrich S; Tielesch B; Rieger M; Nickelsen M; Pott C; Witzens-Harig M; Kneba M; Schmitz N; Ho AD; Dreger P
Cancer; 2011 May; 117(9):1901-10. PubMed ID: 21509767
[TBL] [Abstract][Full Text] [Related]
26. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Othman T; Quan MA; Zhang S; Gaut D; Young PA; Mahmood O; Abdulhaq H; Shieh K; Reid J; Brem EA; Hariharan N; Heyman B; Tuscano J
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):749-756. PubMed ID: 37336714
[TBL] [Abstract][Full Text] [Related]
27. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?
Peterlin P; Leux C; Gastinne T; Roland V; Mahé B; Dubruille V; Delaunay J; Chevallier P; Guillaume T; Blin N; Ayari S; Clavert A; Mohty M; Dousset C; Milpied N; Harousseau JL; Moreau P; Wuilleme S; Moreau A; Le Gouill S
Transplantation; 2012 Aug; 94(3):295-301. PubMed ID: 22797728
[TBL] [Abstract][Full Text] [Related]
28. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL).
Chihara D; Asano N; Ohmachi K; Nishikori M; Okamoto M; Sawa M; Sakai R; Okoshi Y; Tsukamoto N; Yakushijin Y; Nakamura S; Kinoshita T; Ogura M; Suzuki R
Ann Oncol; 2015 May; 26(5):966-973. PubMed ID: 25712457
[TBL] [Abstract][Full Text] [Related]
29. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
30. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review.
Alwasaidi TA; Hamadah A; Altouri S; Tay J; McDiarmid S; Faught C; Allan D; Huebsch L; Bredeson C; Bence-Bruckler I
Cancer Med; 2015 Dec; 4(12):1817-27. PubMed ID: 26432256
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
[TBL] [Abstract][Full Text] [Related]
33. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.
Kumar A; Bantilan KS; Jacob AP; Park A; Schoninger SF; Sauter C; Ulaner GA; Casulo C; Faham M; Kong KA; Grewal RK; Gerecitano J; Hamilton A; Hamlin P; Matasar M; Moskowitz CH; Noy A; Palomba ML; Portlock CS; Younes A; Willis T; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):230-237.e12. PubMed ID: 33558202
[TBL] [Abstract][Full Text] [Related]
34. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Shanmugasundaram K; Goyal S; Switchenko J; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M; Karmali R; Sawalha Y; Hill BT; Ghosh N; Park SI; Epperla N; Bond DA; Badar T; Blum KA; Hamadani M; Fenske TS; Malecek M; Kahl BS; Martin P; Guo J; Flowers CR; Cohen JB
Eur J Haematol; 2021 Sep; 107(3):301-310. PubMed ID: 33973276
[TBL] [Abstract][Full Text] [Related]
35. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
[TBL] [Abstract][Full Text] [Related]
36. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.
Cassaday RD; Gopal AK
Best Pract Res Clin Haematol; 2012 Jun; 25(2):165-74. PubMed ID: 22687452
[TBL] [Abstract][Full Text] [Related]
38. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
40. The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma.
Çakar MK; Tekgündüz E; Dal MS; Merdin A; Başçı S; İskender D; Uğur B; Bekdemir F; Yıldız J; Ulu BU; Bakırtaş M; Yiğenoğlu TN; Batgi H; Kaya AH; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Mar; 26(2):273-278. PubMed ID: 30940050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
